Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial
Top Cited Papers
- 1 December 2005
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 366 (9502) , 2012-2018
- https://doi.org/10.1016/s0140-6736(05)67669-6
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Malaria vaccines in developmentEmerging Drugs, 2005
- Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian childrenVaccine, 2005
- Malaria vaccine: 3 or 6 months' protection?The Lancet, 2005
- A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian AdultsPLoS Medicine, 2004
- Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trialThe Lancet, 2004
- Efficacy of Recombinant Circumsporozoite Protein Vaccine Regimens against ExperimentalPlasmodium falciparumMalariaThe Journal of Infectious Diseases, 2001
- A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalariaNew England Journal of Medicine, 1997
- T Cell Responses to Pre-Erythrocytic Stages of Malaria: Role in Protection and Vaccine Development Against Pre-Erythrocytic StagesAnnual Review of Immunology, 1993
- Malaria, bednets, and mortalityThe Lancet, 1991
- Efficacy of Murine Malaria Sporozoite Vaccines: Implications for Human Vaccine DevelopmentScience, 1987